Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07876128 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002)

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Merck (MSD)
410 trials monitored
See 28 trials at risk
MK-2750 is a trial medicine designed to treat certain solid tumors. MK-2750 is a type of treatment called an antibody drug conjugate (ADC). ADCs attach to a protein on cancer cells and deliver medicine to destroy those cells. The goals of this trial are to learn: * About the safety of MK-2750 and if participants tolerate it. Tolerate means participants will receive trial treatment in the trial unless they need to stop it due to health problems. * How many participants have cancer respond (get smaller or go away) to MK-2750
Trial Details
NCT Number NCT07876128
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Advanced Solid Tumors, Malignant Neoplasm
Related terms Neoplasms
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov